Crescina Transdermic Re-Growth HFSC and Transdermic Anti-Hair Loss Complete Treatment for women is a topical dermo-cosmetic treatment in vials with double function: it helps the physiological hair growth and helps stop the hair-loss.
The packaging contains two vial types: amber vials contain Crescina Transdermic Re-Growth HFSC while transparent vial contain Crescina Transdermic Anti-Hair Loss, combining the basic active ingredients (Hydroxyproline, Aspartic Acid, Enzymatic Activator and Taurine) with Hydrolyzed Yeast Protein and Acetyl Tetrapeptide-3, helpful to reinforce hair from the root (in vitro test on the active ingredients), plus 3 enhancers to facilitate their penetration (Transdermic Technology) through both hair system and scalp. The formulation is enriched with the HSSC Complex.
Specific formulae for Man and Woman. Available in 10+10 and 20+20 vial boxes and in the following dosages: 200, 500, 1300.
- Dosage 200 for initial stages (moderate hair thinning) - Dosage 500 for medium stages (advanced hair thinning) - Dosage 1300 for advanced stages (incipient baldness)
Labo patented Transdermic Technology (Swiss Patent CH 711 466) allows for the active and functional ingredients contained in the formulations to penetrate the different layers of skin and scalp - epidermis and dermis - and reach in a safe and proven way the deepest layers of the skin where they need to act: a real alternative to micro-injections, but without needles. Transdermic Technology is mainly based on the molecular weight of the active substances that, in association with specific enhancers, guarantees the best penetration not only through the follicular opening, but also through the thicker and hardly accessible skin layers of the entire scalp. Transdermic Technology is fundamental for the efficacy of the treatment: without it, it would not be possible to obtain the penetration and the activity results that are normally obtained with the micro-injections. Therefore, Transdermic Technology makes Crescina preparation unique: no other topical product can claim a tested and controlled transdermic activity with ex vivo verified percentages of the penetration values. The 12 “synthetic human” molecules of the new Plate-Like Complex can count on low and very low molecular weights. Their penetration has been tested by means of Franz Diffusion Cells.
A treatment of at least two months is recommended. A 3.5 ml single-dose vial should be applied daily for 5 consecutive days, followed by a two-day break, as shown in the application scheme contained in the package. Available in 20-vial boxes (equivalent to 1-month of treatment) and 40-vial boxes (equivalent to 2-months of treatment). The treatment can be repeated several times a year.
FOR EXTERNAL USE ONLY. DO NOT INJECT. DO NOT SWALLOW. In the event of accidental contact with eyes or mucous membranes, rinse thoroughly with water. Keep out of the reach of children. The preparation contains a mild vasodilator that may cause a slight heat reaction with reddening of the skin for a short time. Wash hands after application.